GSK hands back failed muscular dystrophy drug to Prosensa

Your Health Matters

The signage for the GlaxoSmithKline building is pictured in LondonBy Ben Hirschler LONDON (Reuters) – GlaxoSmithKline has handed back rights to an experimental drug for Duchenne muscular dystrophy to U.S.-listed Dutch biotech firm Prosensa after it failed last year in a critical clinical trial. Both companies said on Monday that Prosensa would now have full and unencumbered rights to drisapersen, as well as other compounds at an earlier stage of development.

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave